In8Bio INAB
NASDAQ INAB
$1.05 +0.06 (+6.06%)
At close: Oct 23, 2026 · 4:00 PM EDT

In8Bio (INAB) Restructuring Costs (2024)

Updated

In8Bio's Restructuring Costs was $1.07 million in FY2024.

Analysis

In8Bio (INAB) Restructuring Costs (2024) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,199.50 Bn 1,168.08 Bn 19.71 Bn
2 Johnson & Johnson 635.17 Bn 555.03 Bn 17.30 Bn
3 AbbVie 504.69 Bn 477.85 Bn 12.70 Bn
4 Merck 358.43 Bn 312.86 Bn 12.21 Bn
5 Novartis Ag 288.36 Bn 252.75 Bn 11.24 Bn
6 Astrazeneca 265.78 Bn 239.54 Bn 12.86 Bn
7 Amgen 237.46 Bn 192.86 Bn 7.24 Bn
8 Gilead Sciences 193.65 Bn 167.76 Bn 6.22 Bn
9 Pfizer 171.05 Bn 118.00 Bn 10.94 Bn
10 In8Bio 20.44 Mn -57.91 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2024 1.07 Mn
API Access

In8Bio Restructuring Costs API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=restructuring-costs&ticker=INAB&period=max&api_key=YOUR_API_KEY